About Us
Blog
Contains articles from Dante and our partners discussing the latest research, publications, and updates about genome sequencing.
About Us
Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting
Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting
About Us
Dante Genomics to present at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Us
Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing Solutions for Women’s Health in Europe
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Us
Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.
Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.
About Us
Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit
Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.
Diagnostics
TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Diagnostics
Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery
Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases.
Diagnostics
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).
Genome Sequencing
Dante selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC).